MedTrace Logo

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload

NCT01369719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2011-06-14

No results posted yet for this study

Summary

Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients. The aim of this study is to compare the efficacy and safety of osveral and desferal in transfusional iron overload patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.

Conditions

  • Thalassemia
  • Iron Overload
  • Transfusion Related Complications

Interventions

DRUG

osveral

receive 20 mg/kg daily orally

DRUG

Desferal

40-50mg/Kg for 6 nights in each week subcutaneously

Sponsors & Collaborators

  • Hormozgan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Fariba Mansoori, Resident · Hormozgan University of Medical Sciences (HUMS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-01-31
Completion
2011-05-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01369719 on ClinicalTrials.gov